294 results about "Peptide conjugate" patented technology

Disclosed is an immunity-inducing agent having excellent ease of production and high immunostimulatory activity, the immunity-inducing agent comprising, as an active component, a polynucleotide / peptide conjugate in which an antigenic peptide is covalently bound to a single-stranded polynucleotide or polynucleotide derivative. Also disclosed is a pharmaceutical composition comprising said immunity-inducing agent.

The invention relates to peptides and / or peptide conjugates as described herein. The invention also relates to detergents or cleaning agents comprising at least one peptide and / or peptide conjugate as defined herein. Furthermore, the invention relates to a method for cleaning textiles and / or hard surfaces using the aforementioned detergent or cleaning agent and to the use of a peptide and / or peptide conjugate as a dirt-releasing and / or dirt-repelling active ingredient in the washing and / or cleaning of textiles and / or hard surfaces, and for improving the cleaning performance of a detergent or cleaning agent containing said peptide and / or peptide conjugate.

Provided are compositions and methods that include binding partners that specifically bind to peptide conjugate / MHC complex, wherein the peptide conjugate / MHC complex comprises a peptide conjugate that is formed by the covalent reaction of a targeted covalent inhibitor with a peptide. The binding partners are provided as antibodies or antibody derivatives that specifically bind to the peptide conjugate / MHC complexes described herein.

The invention relates to peptides and / or peptide conjugates as described herein. The invention further relates to washing or cleaning agents comprising at least one peptide and / or peptide conjugate as defined herein. The invention also relates to a method for cleaning textiles and / or hard surfaces using said washing or cleaning agent and the use of a peptide and / or peptide conjugate as a dirt-removing and / or dirt-repellent agent in washing and / or cleaning textiles and / or hard surfaces, as well as for improving the cleaning performance of a washing or cleaning agent containing this peptide and / or peptide conjugate.

The invention belongs to the technical field of biological medicines, and particularly relates to an umbilical cord mesenchymal stem cell preparation and application thereof to treatment of hepatic diseases. The umbilical cord mesenchymal stem cell preparation comprises umbilical cord mesenchymal stem cells from the third generation to the sixth generation, a GPR55 peptide conjugate and pharmaceutically acceptable auxiliary materials. And the amino acid sequence of the GPR55 peptide conjugate is selected from CKKNSPTLC, CKKNTPTQC or CKKNSPTGC. The umbilical cord mesenchymal stem cell preparation can obviously reduce alpha-SMA and COL-I secreted by hepatic stellate cells and inhibit activation of the hepatic stellate cells, and the fact that the umbilical cord mesenchymal stem cell preparation has anti-hepatic fibrosis activity is further verified in a CCl4 induced hepatic fibrosis model.

The present invention relates generally to the field of medicine. More particularly, the present invention relates to polypeptide conjugates, compositions and methods for promoting immune tolerance to CRISPR-Cas (clustered regularly spaced short palindromic repeats-CRISPR associated proteins) systems for use in genomic engineered gene therapy.

The invention provides a D-configuration oncolytic peptide and [Tyr3] Octreoate-D-configuration oncolytic peptide conjugate as well as a preparation method and application of a fluorescent probe of the D-configuration oncolytic peptide and [Tyr3] Octreoate-D-configuration oncolytic peptide conjugate, and belongs to the fields of polypeptide preparation and biological medicine. According to the invention, a series of [Tyr3] Octreoate-D-configuration oncolytic peptide conjugates and fluorescent probes thereof are synthesized, and are prepared by a solid-phase polypeptide synthesis method. Experiments prove that the [Tyr3] Octreoate-D-configuration oncolytic peptide conjugate obtained by the invention can significantly improve the stability of the oncolytic peptide and improve the selectivity of the oncolytic peptide to tumor cells, and shows a stronger in-vivo and in-vitro anti-tumor effect. Meanwhile, the D-configuration oncolytic peptide conjugate fluorescent probe prepared by the invention realizes space-time tracing and cell localization of the oncolytic peptide, so that the D-configuration oncolytic peptide conjugate fluorescent probe has good practical application value.

Disclosed are conjugates of an oligonucleotide and a peptide covalently bonded or linked via a linker to the oligonucleotide, the peptide including at least one cationic domain comprising at least 4 amino acid residues and at least one hydrophobic domain comprising at least 3 amino acid residues, provided that the peptide includes a total of 7 to 40 amino acid residues and does not include any artificial amino acid residues; and the oligonucleotide including a total of 12 to 40 contiguous nucleobases, where at least 12 contiguous nucleobases are complementary to a target sequence in a human dystrophin gene.

The present invention relates to a drug conjugate comprising two different cyclic peptide ligands conjugated to an effector, such as a drug molecule, a pharmaceutical composition comprising the drug conjugate, and the use of the drug conjugate in the prevention or treatment of a disease, such as cancer.

To provide peptide ligands, and peptide complexes comprising the peptide ligands conjugated to a second peptide.SOLUTION: The present invention provides a peptide ligand that binds to Nectin-4 present on a cancer cell, or a pharmaceutically acceptable salt thereof, the peptide ligand comprising a polypeptide comprising at least three reactive groups separated by at least two loop sequences, and a molecular scaffold that forms covalent bonds with the reactive groups of the polypeptide, such that at least two polypeptide loops are formed on the molecular scaffold, wherein the polypeptide is a modified derivative of a specific sequence.SELECTED DRAWING: None

The present disclosure relates to peptide compounds and conjugate compounds, processes, methods and uses thereof for treating cancer. For example, the compounds can comprise compounds of formula(SEQ ID NO: 1)X1X2X3X4X5GVX6AKAGVX7NX8FKSESY(I)(SEQ ID NO: 2)(X9)nGVX10AKAGVX11NX12FKSESY(II)(SEQ ID NO: 3)YKX13LRRX14APRWDX15PLRDPALRX16X17L(III)(SEQ ID NO: 4)YKX18LRR(X19)nPLRDPALRX20X21L(IV)(SEQ ID NO: 5)IKLSGGVQAKAGVINMDKSESM(V)(SEQ ID NO: 6)IKLSGGVQAKAGVINMFKSESY(VI)(SEQ ID NO: 7)IKLSGGVQAKAGVINMFKSESYK(VII)(SEQ ID NO: 8)GVQAKAGVINMFKSESY(VIII)(SEQ ID NO: 9)GVRAKAGVRNMFKSESY(IX)(SEQ ID NO: 10)GVRAKAGVRN(Nle)FKSESY(X)(SEQ ID NO: 11)YKSLRRKAPRWDAPLRDPALRQLL(XI)(SEQ ID NO: 12)YKSLRRKAPRWDAYLRDPALRQLL(XII)(SEQ ID NO: 13)YKSLRRKAPRWDAYLRDPALRPLL(XIII)wherein X1 to X21 and n can have various different valuesand wherein at least one protecting group and / or at least one labelling agent is optionally connected to said peptide compound at an N- and / or C-terminal end.

Provided herein are conjugates comprising a promoter peptide conjugated to an agent, such as an antibody or antigen-binding fragment thereof. The promoter peptides promote internalization of an agent (e.g., an antibody or antigen binding fragment thereof). The promoter peptides may also promote internalization of a target protein into a cell when coupled to an agent that binds to the target protein (e.g., a receptor). Also provided are methods of using the conjugates provided herein, for example, for promoting uptake of an antibody or antigen-binding fragment thereof into a cell, for promoting uptake of a target protein into a cell.

Provided herein are peptides and peptide conjugates comprising a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. The peptides may be used for blood glucose management and treating conditions such as diabetes, obesity, non-alcoholic fatty liver disease (NAFLD), and non-alcoholic steatohepatitis (NASH).

The present invention relates to a preparation of a polypeptide conjugate using an aptamer containing oxanine. In particular, the present invention relates to a composition for preparing a conjugate of a polypeptide, the composition comprising an aptamer containing oxanine, and a method of preparing a conjugate of a polypeptide using the same. The present invention also relates to a conjugate comprising a polypeptide and an aptamer containing oxanine, and a conjugate comprising a polypeptide and a drug.

The present invention relates to peptide conjugates of cytotoxins such as topoisomerase I inhibitors which are useful for the treatment of diseases such as cancer.

Disclosed herein is a cortisol sensor, comprising or consisting of: i) a metal nanoparticle; ii) a plurality of cortisol binding ligands conjugated to the surface of the metal nanoparticle; and iii) a plurality of peptides conjugated to the surface of the metal nanoparticle, for reducing non-specific binding of the cortisol binding ligands and / or improving stability of the metal nanoparticle in solution. In particular, the metal nanoparticle is a gold nanoparticle, the cortisol binding ligand is a cortisol DNA aptamer, and the peptide is CALNN. Also disclosed is a method of detecting the presence or quantity of cortisol in a sample, comprising or consisting the steps of: a) providing the cortisol sensor; b) contacting the cortisol sensor to the sample in a saline environment; and c) determining the degree of aggregation of the cortisol sensor. In particular, the degree of aggregation is measured by UV-visible spectroscopy.

Featured are devices, systems, and methods of use for detecting binding of polynucleotide-peptide conjugate-major histocompatibility complex (pMHC) monomers to a T cell receptors (TCR) on a T cell, and the use of a peptide library to detect binding of antigenic peptides in a pMHC monomer to a T cell receptor (TCR) on a T cell.

A carrier peptide conjugate comprising one or more carrier peptide groups and one or more functional groups; each carrier peptide group is linked to at least one of the functional groups or at least one further carrier peptide group via at least one linking group, and each functional group is linked to at least one of the carrier peptide groups or at least one further functional group via at least one linking group; the length of each carrier peptide group is 5-40 amino acid residues, and each carrier peptide group contains one or more amino acid sequence segments which are connected in series and are shown as a formula (I); each functional group is independently one of a functional oligonucleotide group and a delivery aid group, and at least one functional group is a functional oligonucleotide group. The carrier peptide conjugate provided by the invention can be effectively targeted to the kidney or kidney tissue.

Provided herein are Camptothecin Conjugates, Camptothecin-Linker Compounds, Camptothecin Compounds, intermediates thereof, and method of preparing the same. Also provided herein are methods of treating cancer and autoimmune diseases with the Conjugates described herein.

Provided are compositions and methods that include binding partners that specifically bind to a peptide conjugate / MHC complex comprising a peptide conjugate that is formed by the covalent reaction of a targeted covalent inhibitor with a peptide. The binding partners are provided as antibodies and antibody derivatives that specifically bind to the peptide conjugate / MHC complexes.

The present invention provides, in some embodiments, methods, compositions, systems, and kits comprising nano-satellite complexes comprising: a core nanoparticle complex comprising a biocompatible coating surrounding a nanoparticle core; 3-25 satellite particles attached to, or absorbed to, said biocompatible coating; a plurality of antigenic peptides conjugated to, or absorbed to, said satellite particles; and at least one additional property. In other embodiments, provided herein are nano-satellite complexes comprising: a core nanoparticle complex comprising a biocompatible coating surrounding a nanoparticle core; a plurality of satellite particles attached to, or absorbed to, said biocompatible coating; a plurality of antigenic peptides conjugated to, or absorbed to, said satellite particles; and a plurality of LIGHT (TNFSF14) peptides conjugated to, or absorbed to, said satellite particles. In some embodiments, administration of the nanosatellite complexes to a subject with cancer achieves long-term cancer remission (e.g., when combined with an immune checkpoint inhibitor, such as αPD1).

The invention provides a compound comprising one, two, three or more non-natural HRC sequence of a viral spike peptide conjugated to a hydrophobic moiety via an optional linker. The hydrophobic moiety can be a membrane integrating ligand, such as a cholesterol, a sphingolipid, a glycolipid, a glycerophospholipid. The non-natural viral spike peptide is preferably a coronavirus spike protein characterized by one or more D-amino acids. The peptides of the invention inhibit viral fusion. The invention includes compositions for the delivery of compounds of the invention, such as pulmonary or nasal delivery. The invention also provides a method of treating or preventing a viral infection, including for example a SARS-CoV-2 (COVID-19) infection, in a subject in need thereof comprising administering an effective amount of a compound of the invention.

The invention discloses an STING agonist polypeptide conjugate as well as a composition and application thereof, and belongs to the field of medicinal chemistry, an STING agonist and a straight-chain peptide or a cyclic peptide are directly connected or connected through a linking group, the formed conjugate can target a tumor microenvironment, and the STING agonist is controllably released in specific time and space, so that the tumor microenvironment is inhibited, and the tumor microenvironment is inhibited. Therefore, the drug enrichment amount of the tumor site is increased, the drug treatment efficiency and bioavailability are improved, the toxic and side effects are reduced, and the purposes of effect enhancement and toxicity reduction are achieved. According to the STING agonist polypeptide conjugate, the targeting property of STING agonist drugs on tumor tissues is improved, the toxic and side effects on normal tissues are reduced, the STING agonist polypeptide conjugate is a brand-new immune agonist type coupling drug, and a new scheme is provided for tumor immunotherapy research.

The present invention relates to a linker compound having a fused nitrogen-containing heteroaromatic ring and a vinyl substituent for conjugating to a protein or peptide. The present invention further relates to a conjugate comprising the linker and an active agent and to a conjugate comprising the linker, a protein or peptide, and an active agent, such as a drug or labelling moiety. More specifically, the conjugate may be an antibody conjugate, such as an antibody drug conjugate (ADC).

Compositions, methods and treatment regimens for mutant fibroblast growth factor-21 (FGF-21) peptide conjugates for the treatment of severe hypertriglyceridemia are provided.

An embodiment of the present invention relates to: a cancer antigen peptide nanostructure comprising an assembly of cancer antigen peptides conjugated with deoxycholic acid; a method for preparing same; and use thereof. The inventors of the present invention confirmed that the nanostructure of the present invention effectively stimulates the maturation of dendritic cells, migrates to lymph nodes, and activates T cells. Also, in a cancer cell model, significant infiltration of cytotoxic T lymphocytes into primary tumors was observed, and an anti-metastatic effect was confirmed. Therefore, the nanostructure according to the present invention can be effectively used as a promising immunotherapy platform that can be applied to various intractable cancers.

Provided herein are peptides and peptide conjugates comprising a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. The peptides may be used for blood glucose management and treating conditions such as diabetes, obesity, non-alcoholic fatty liver disease (NAFLD), and non-alcoholic steatohepatitis (NASH).

To introduce material to cells, contemporary medicinal constructs rely on the uptake mechanisms of the cell membrane. This puts major restrictions on the types of utilizable materials (e.g., charge compatible), specifications (e.g., 100 nanometer scale or less) and organizations (mostly simplistic spheroids); this is the regime of nanoparticles, protein / peptide conjugates etc. However, the focus and novelty of the innovation presented are constructs which can still achieve this membrane interaction to connect to cells yet the constructs themselves remain outside of the cell, thus establishing a network by which to transfer materials. These can surpass the aforementioned limitations as well as create entirely new application spaces as these new constructs enable different desired distribution patterns and exchanged material.

This disclosure relates to structurally-stabilized (e.g., stapled, e.g., hydrocarbon stapled) Ebolavirus peptides and variants thereof, and structurally-stabilized (e.g., stapled, e.g., hydrocarbon stapled) Ebolavirus peptides and variants thereof, conjugated with polyethylene glycol (PEG) and / or cholesterol (or a variant thereof, e.g., thiocholesterol), e.g., a generated PEG(n)-cholesterol or PEG(n)-thiocholesterol derivatization to further optimize activity, and methods for using such structurally-stabilized peptide conjugates in the prevention and treatment of an Ebolavirus infection or disease in a subject (e.g., human, non-human primate, or fruit bat). The disclosure also relates to methods of using such structurally-stabilized peptides and conjugates in the prevention and treatment of a Marburg virus infection, a Bombali ebolavirus infection, or a Mengla dianlovirus infection in a subject.

The present invention relates to peptide conjugates that comprise a plant-derived oligopeptide capable of crossing the blood-brain barrier (BBB) and a therapeutic or diagnostic agent. The BBB-penetrating oligopeptide is an oligopeptide according to Formula I, Asp–R2–Gly–Leu–R5–R6–R7–Leu–Gly–R10–R11–R12, wherein R2 represents Arg, Lys, Cyt, D-Arg or Orn; R5 represents Phe, Arg, Lys, His, Trp, Tyr, D-Tyr, D-Phe, Orn, 4-aminophenylalanine or 3-phenylpropionate; R6 represents Pro, Leu, Glu or Lys; R7 represents Phe or Trp; R10, R11 and R12 each independently represent Lys, Arg or Orn; or an oligopeptide according to Formula II, Glu–R2'–R3'–Gly–R5'–R6'–Glu–R8'–R9'–R10'–Glu–R12'–Leu–Pro–Gly, wherein R2', R3', R8', R10' and R12' each independently represent Lys, Arg or Orn; R5' represents Phe, Ile, Arg, Lys, His, Trp, Tyr, D-Tyr, D-Phe, 4-aminophenylalanine, or 3-phenylpropionate; R6' represents Met, Leu, Ile, Asn, norleucin, D-norleucin, seleno- methionine or D / L-2-hydroxy-(4-methylseleno)butanoic acid; and R9' represents Leu or Ile. The conjugates comprising a BBB-penetrating oligopeptide compound and a therapeutic agent can be used in treatments for diseases of the central nervous system (CNS). Furthermore, conjugates with a BBB-penetrating oligopeptide compound and a diagnostic agent can be used in both in vivo and in vitro diagnostic methods.